Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1959 1
1960 1
1963 1
1965 4
1966 11
1967 12
1968 14
1969 16
1970 15
1971 13
1972 38
1973 74
1974 109
1975 111
1976 108
1977 110
1978 116
1979 154
1980 111
1981 139
1982 177
1983 197
1984 173
1985 189
1986 204
1987 259
1988 289
1989 341
1990 353
1991 384
1992 469
1993 423
1994 425
1995 394
1996 374
1997 467
1998 511
1999 458
2000 510
2001 542
2002 534
2003 595
2004 645
2005 644
2006 746
2007 803
2008 846
2009 938
2010 1004
2011 1118
2012 940
2013 1013
2014 965
2015 959
2016 893
2017 808
2018 803
2019 348
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

21,067 results
Results by year
Filters applied: . Clear all
Page 1
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid AS, et al. Cochrane Database Syst Rev 2018 - Review. PMID 30019766 Free PMC article.
Updated
Most studies assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet.Meta-analysis and sensitivity analyses suggested little or no effect of increasing LCn3 on all-cause mortality (RR 0.98, 95% CI 0.90 to 1.03, 92,653 participants; 8189 deaths in 39 trials, high-quality evidence), cardiovascular mortality (RR 0.95, 95% CI 0.87 to 1.03, 67,772 participants; 4544 CVD deaths in 25 RCTs), cardiovascular events (RR 0.99, 95% CI 0.94 to 1.04, 90,378 participants; 14,737 people experienced events in 38 trials, high-quality evidence), coronary heart disease (CHD) mortality (RR 0.93, 95% CI 0.79 to 1.09, 73,491 participants; 1596 CHD deaths in 21 RCTs), stroke (RR 1.06, 95% CI 0.96 to 1.16, 89,358 participants; 1822 strokes in 28 trials) or arrhythmia (RR 0.97, 95% CI 0.90 to 1.05, 53,796 participants; 3788 people experienced arrhythmia in 28 RCTs). ...AUTHORS' CONCLUSIONS: This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. ...
Most studies assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compare …
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump DB, et al. Pharmacol Ther 2018 - Review. PMID 28723414 Free PMC article.
We also provide an in-depth rationale for the use of dietary ω3 polyunsaturated fatty acid (ω3 PUFA) supplements as a treatment option for NAFLD. ...Finally, our discussion will address the strengths and limitations of ω3 PUFA supplements use in NAFLD therapy....
We also provide an in-depth rationale for the use of dietary ω3 polyunsaturated fatty acid (ω3 PUFA) supplements as a treatmen …
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid AS, et al. Cochrane Database Syst Rev 2018. PMID 30521670 Free PMC article.
Most studies assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet. ...AUTHORS' CONCLUSIONS: This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. ...
Most studies assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compare …
Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action
Scorletti E and Byrne CD. Mol Aspects Med 2018 - Review. PMID 29544992
Meta-analyses (of predominantly dietary studies and small trials) have tended to support the assertion that omega-3 fatty acids are beneficial in decreasing liver lipid, but recent randomised controlled trials have produced conflicting data. ...
Meta-analyses (of predominantly dietary studies and small trials) have tended to support the assertion that omega-3 fatty acids are b …
Effect of dietary supplementation with omega-3 fatty acid and gamma-linolenic acid on acne vulgaris: a randomised, double-blind, controlled trial.
Jung JY, et al. Acta Derm Venereol 2014 - Clinical Trial. PMID 24553997 Free article.
This study was undertaken to evaluate the clinical efficacy, safety, and histological changes induced by dietary omega-3 fatty acid and γ-linoleic acid in acne vulgaris. A 10-week, randomised, controlled parallel dietary intervention study was performed in 45 participants with mild to moderate acne, which were allocated to either an omega-3 fatty acid group (2,000 mg of eicosapentaenoic acid and docosahexaenoic acid), a γ-linoleic acid group (borage oil containing 400 mg γ-linoleic acid), or a control group. ...
This study was undertaken to evaluate the clinical efficacy, safety, and histological changes induced by dietary omega-3 fatty acid a …
21,067 results
Jump to page
Feedback